These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 7965271)
1. Cell biology and genetics of angiotensin in cardiovascular disease. Dzau VJ J Hypertens Suppl; 1994 Jul; 12(4):S3-10. PubMed ID: 7965271 [TBL] [Abstract][Full Text] [Related]
2. Mechanism of protective effects of ACE inhibition on coronary artery disease. Dzau VJ Eur Heart J; 1998 Sep; 19 Suppl J():J2-6. PubMed ID: 9796834 [TBL] [Abstract][Full Text] [Related]
3. [The significance of converting enzyme inhibitor angiotensin I to angiotensin II in treatment of patients with coronary disease]. Halawa B Pol Merkur Lekarski; 1998 Jan; 4(19):32-4. PubMed ID: 9553407 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors]. Tschudi MR; Noll G; Lüscher TP Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890 [TBL] [Abstract][Full Text] [Related]
5. Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide. Gibbons GH Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-18-25. PubMed ID: 9422848 [TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
9. Blocking the renin-angiotensin system: dual- versus mono-therapy. Ravandi A; Teo KK Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282 [TBL] [Abstract][Full Text] [Related]
10. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Bertrand ME Curr Med Res Opin; 2004 Oct; 20(10):1559-69. PubMed ID: 15462689 [TBL] [Abstract][Full Text] [Related]
11. Regulation of vascular smooth-muscle cell growth by angiotensin II. Pratt RE Blood Press Suppl; 1996; 2():6-9. PubMed ID: 8913533 [TBL] [Abstract][Full Text] [Related]
13. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies. Pasquale PD; Stefano GD; Paterna S Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. Katoh M; Egashira K; Mitsui T; Chishima S; Takeshita A; Narita H J Mol Cell Cardiol; 2000 Jan; 32(1):73-83. PubMed ID: 10652192 [TBL] [Abstract][Full Text] [Related]
15. The sympathetic nervous system and ischaemic heart disease. Remme WJ Eur Heart J; 1998 Jun; 19 Suppl F():F62-71. PubMed ID: 9651738 [TBL] [Abstract][Full Text] [Related]
16. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure]. Schunkert H; Holmer SR; Riegger G Z Kardiol; 1993; 82 Suppl 4():1-6. PubMed ID: 8147057 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Brugts JJ; Ferrari R; Simoons ML Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059 [TBL] [Abstract][Full Text] [Related]
18. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors. Galderisi M; de Divitiis O J Cardiovasc Pharmacol; 2008 Jun; 51(6):523-31. PubMed ID: 18520954 [TBL] [Abstract][Full Text] [Related]